EmphyCorp Patents

Global Drug Patents have been granted in Spain, Austria, UK, Ireland, Italy, Germany, France, Sweden, Canada, Mexico, Australia, New Zealand, China, Philippines, South Africa, Japan, Taiwan, and Brazil.

This does not include New PCT Patents filed or to be filed. All our Patents cover the use of pyruvate to treat lung and sinus diseases with sodium pyruvate or any pyruvate analog including ethyl pyruvate and amino acid pyruvates.

Our recent granted Chinese Patent was granted for the treatment of all lung diseases with any and all Patented or Non-patented Drugs, providing EmphyCorp with a huge range of Patent protected products that can be used in China. 

EmphyCorp Drug - USA Patents 

Patent CSI-11:  Filed February  24, 2017 For the treatment of Pulmonary Diseases and All Lung Diseases with Hypoxemia 

Patent:  9,675,569 issued June 13 2017 Method for treating a Pulmonary Disease state in mammals by up or down regulating indigenous in vivo levels of inflammatory agents in mammalian cells. Claims for the treatment of lung and nasal diseases, and for smoking cessation.

Patent:  8,211,943 issued July 3 2012  Method for treating a Pulmonary Disease state in mammals by up or down regulating indigenous in vivo levels of inflammatory agents in mammalian cells. Claims for the treatment of lung and nasal diseases.  

Patent:  8,114,907 issued August 8 2007 Method for treating a Pulmonary Disease state in mammals by up or down regulating indigenous in vivo levels of inflammatory agents in mammalian cells. Claims for the treatment of lung diseases. 

Patent:  6,689,810 (Issued February 10, 2004) Title: Method for treating Pulmonary Disease states in mammals by altering indigenous in vivo levels of nitric oxide. 

Patent:  6,623,723 (Issued September 23, 2003)  Method for treating Bronchial Constriction and Bronchospasm.

 

 

Our Products

Please see "Our Products" Tab on the Home Page